Abstracts tagged "gout"

Abstract Number: 1096 • ACR Convergence 2024
Exploring Multi Factorial Model for the Prediction of Gout in Patients with Hyperuricemia
Shay Brikman¹, Liel Serfaty, MA², Ran Abuhasira, MD, PhD³, Naomi Schlesinger⁴, Nadav Rappoport⁵ and Amir Bieber⁶, ¹Emek Medical Center, Afula, Israel, ²Department of Software and Information Systems Engineering, Ben-Gurion University of the Negev, Be'er Sheva, Israel, ³Clinical Research Center, Soroka University Medical Center, Be'er Sheva, Israel, ⁴University of Utah, Salt Lake City, UT, ⁵Ben-Gurion University of the Negev, Beer-Sheva, Israel, ⁶Emek Medical Center, Clalit Health Services, Raanana, Israel
Background/Purpose: Hyperuricemia (HU) is considered the most important factor preceding Gout. Yet, only a portion of hyperuricemic people develop Gout. Using a machine learning modeling…
Abstract Number: 1992 • ACR Convergence 2024
Gout FlaresFollowingImmune Checkpoint Inhibitors Treatment
Austen herron¹, Miao Ting Lai², Naomi Schlesinger³, Sauer brian⁴, Jorge Rojas⁵, shardool Patel³, Madeline O’Sullivan³, grant Cannon⁶ and Tawnie Braaten³, ¹Salt Lake City VA and University of Utah, Salt Lake City, UT, ²University of Utah and Salt Lake City VA, salt lake city, ³University of Utah, Salt Lake City, UT, ⁴Salt Lake City VA/University of Utah, Salt Lake City, UT, ⁵Seattle VA, Mexico, Mexico, ⁶University of Utah and Salt Lake City VA, Salt Lake City, UT
Background/Purpose: Immune checkpoint inhibitors (ICIs) produce immune-related adverse events in patients with rheumatic diseases that can often present as a flare of the underlying condition.…
Abstract Number: 2020 • ACR Convergence 2024
Prediction of the Response of Patients with Chronic Uncontrolled Gout to Pegloticase
Peter Lipsky¹ and anthony yeo², ¹AMPEL BioSolutions, Charlottesville, VA, ²Independent consultant, Ann arbor, MI
Background/Purpose: Pegloticase is a pegylated recombinant uricase approved for treatment of chronic uncontrolled gout. Because of the development of anti-drug antibodies (ADA), persistent urate lowering…
Abstract Number: 0273 • ACR Convergence 2024
Barriers and Facilitators for Outpatient Follow-Up After an Acute Gout Flare: A Qualitative Research Study
Elizabeth Lopez¹, Lesley Jackson², Kenneth Saag³ and Maria I. ("Maio") Danila⁴, ¹University of Alabama at Birmingham, Montgomery, AL, ²University of Alabama at Birmingham, Birmingham, AL, ³The University of Alabama at Birmingham, Birmingham, AL, ⁴University of Alabama at Birmingham (UAB), Birmingham VA Medical Center, Birmingham, AL
Background/Purpose: Many people with gout utilize the emergency department (ED) for acute gout care, but many do not receive subsequent adequate outpatient care for long-term…
Abstract Number: 1067 • ACR Convergence 2024
Initiation of Urate-Lowering Therapy in Patients Hospitalized with Gout Flare at a Single Center: Opportunity for Quality Improvement
Ali Nasir¹ and Nasir Khan², ¹Trinity Health Grand Rapids/Michigan State University, Grand Rapids, MI, ²Trinity Health Grand Rapids, Grand Rapids, MI
Background/Purpose: Hospitalizations for gout flare have been increasing, doubling between 1993 to 2011 from 4.4 to 8.8 admissions per 100000 adults. Despite this increase, urate-lowering therapy (ULT)…
Abstract Number: 1097 • ACR Convergence 2024
CERT Score as a Potential Tool to Predict Cardiovascular Risk in Gout and Hyperuricemia
Blanka Stiburkova¹, Aleš Kvasnička², Barbora Pisklakova², Jakub Rozhon², Karel Pavelka³ and David Friedecky², ¹Institute of Rheumatology, Prague, Czech Republic and Department of Paediatrics and Inherited Metabolic Disorders, 1st Faculty of Medicine, Charles University and General University Hospital in Prague, Czech Republic, Prague, Czech Republic, ²Laboratory for Inherited Metabolic Disorders, Department of Clinical Biochemistry, University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacký University Olomouc, Olomouc, Czech Republic, Olomouc, Czech Republic, ³Institute of Rheumatology and Charles University, Praha, Czech Republic
Background/Purpose: Asymptomatic hyperuricemia and gout are two clinical conditions associated with a high risk of cardiovascular events and mortality. Recent data suggest that the number…
Abstract Number: 2005 • ACR Convergence 2024
Impact of Anti-drug Antibodies on the Efficacy of SEL-212 in Patients with Chronic Gout Refractory to Conventional Therapy
Puja Khanna¹, Vibeke Strand², Atul Singhal³, Herbert Baraf⁴, Rehan Azeem⁵, Wesley DeHaan⁶, Sheldon Leung⁵, Hugues Santin-Janin⁷, Aletta Falk⁸ and Alan Kivitz⁹, ¹University of Michigan, Ann Arbor, MI, ²Division of Immunology/Rheumatology, Stanford University, Palo Alto, CA, ³Southwest Arthritis Research Group, Mesquite, TX, ⁴Center for Rheumatology and Bone Research, Wheaton, MD, ⁵Sobi Inc., Waltham, MA, ⁶Sobi, Inc, Waltham, MA, ⁷Sobi, BETTENDORF (68560), France, ⁸Sobi, Stockholm, Sweden, ⁹Altoona Center for Clinical Research, Duncansville, PA
Background/Purpose: SEL-212 is a once-monthly, investigational, two-component infusion therapy consisting of pegadricase (SEL-037, a pegylated uricase) and immune-tolerizing nanoparticles containing sirolimus (SEL-110), for the treatment…
Abstract Number: 2021 • ACR Convergence 2024
The Dual Benefits of Sodium-Glucose Cotransporter-2 Inhibitors for Recurrent Nephrolithiasis and Gout Flares Among Gout Patients with Type 2 Diabetes: New User, Active Comparator Target Trial Emulation Studies
Natalie McCormick¹, Chio Yokose², Leo Lu³, Deborah Wexler¹, J. Antonio Avina-Zubieta⁴, Mary A. De Vera⁵, saiajay chigurupati¹, Kiara Tan¹, Chixiang Chen⁶, Rozalina McCoy⁶, Gary Curhan⁷ and Hyon K. Choi⁸, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital, Waltham, MA, ³Arthritis Research Canada, Vancouver, BC, Canada, ⁴Arthritis Research Canada, University of British Columbia, Vancouver, BC, Canada, ⁵University of British Columbia, Faculty of Pharmaceutical Sciences, Vancouver, BC, Canada, ⁶University of Maryland, School of Medicine, Baltimore, MD, ⁷Brigham and Women's Hospital, Boston, MA, ⁸Massachusetts General Hospital, Lexington, MA
Background/Purpose: Nephrolithiasis and gout are both common, extremely painful conditions which frequently coexist, along with type 2 diabetes (T2D). Sodium-glucose cotransporter-2 inhibitors (SGLT2i), first approved…
Abstract Number: 0274 • ACR Convergence 2024
Cost-effectiveness of Low Dose Colchicine Prophylaxis When Starting Allopurinol Using the “Start-Low Go-Slow” Approach for Gout
Yana Pryymachenko¹, Ross Wilson¹, Haxby Abbott¹, Nicola Dalbeth² and Lisa Stamp³, ¹University of Otago, Dunedin, New Zealand, ²University of Auckland, Auckland, New Zealand, ³University of Otago, Christchurch, Christchurch, New Zealand
Background/Purpose: To investigate the cost-effectiveness of low-dose colchicine prophylaxis for reducing gout flares when starting allopurinol using the “start-low go-slow” approach.Methods: This was a pre-planned…
Abstract Number: 1071 • ACR Convergence 2024
Rapid Access Microscopy and Real Time Case Discussion via a Secure Messaging App Improves Diagnostic Accuracy and Management of Acute Hot Swollen Joints
Anouchka Lewis¹, John Stack², Oisin Corish², Callum Swift², Tomás Breslin², Frank Lyons², Eavan Muldoon², Cian McDermott², Sharon Cowley², Helina Alemayehu², Oliver Boughton², Khaled Taha² and Geraldine McCarthy², ¹The Mater Misericordiae University Hospital, Dublin, Ireland, ²Mater Misericordiae University Hospital, Dublin, Ireland
Background/Purpose: Patients with acute swollen joints are often presumed to have septic arthritis, leading to treatment with intravenous antibiotics and arthroscopic washout. Previously at our…
Abstract Number: 1099 • ACR Convergence 2024
Distinct Metabolomic Signatures of Insulinemia and Incident Gout Risk: A Prospective Cohort Study Among Women
Sharan Rai¹, Hyon K. Choi², Chio Yokose¹ and Natalie McCormick¹, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital, Lexington, MA
Background/Purpose: Gout and the metabolic syndrome frequently coexist. Intravenous insulin has been shown to raise serum urate levels in physiologic studies, and a Mendelian Randomization…
Abstract Number: 2006 • ACR Convergence 2024
Gout Flares After Stopping Anti-inflammatory Prophylaxis During the Early Phases of Urate-Lowering Therapy
Lisa Stamp¹, Chris Frampton¹, James O'Dell², Ted Mikuls², Jeff Newcomb² and Nicola Dalbeth³, ¹University of Otago, Christchurch, Christchurch, New Zealand, ²University of Nebraska Medical Center, Omaha, NE, ³University of Auckland, Auckland, New Zealand
Background/Purpose: Anti-inflammatory prophylaxis is recommended during the initial period of urate-lowering therapy (ULT) as gout flares are common during this time. The aim of this…
Abstract Number: 2022 • ACR Convergence 2024
Could Initiation of Sodium Glucose Co-Transporter-2 Inhibitors Reduce the Need for Conventional Urate-Lowering Therapy and Flare Medications in Patients with Gout?Population-Based Target Trial Emulation Studies
Natalie McCormick¹, Chio Yokose², Leo Lu³, Sharan Rai¹, Gregory Challener¹ and Hyon K. Choi⁴, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital, Waltham, MA, ³Arthritis Research Canada, Vancouver, BC, Canada, ⁴Massachusetts General Hospital, Lexington, MA
Background/Purpose: Sodium-glucose cotransporter-2 inhibitors (SGLT2i) lower serum urate levels and are associated with reduced risk of incident gout as well as recurrent flares [Annals IM…
Abstract Number: 0275 • ACR Convergence 2024
Targeting IRAK4 in Monosodium Urate Crystals Induced Inflammation
Sadiq Umar¹ and Sriram Ravindran², ¹University of Illinois at Chicago, Chicago, IL, ²University of Illinois, Chicago
Background/Purpose: Gout, the leading cause of inflammatory arthritis, is becoming increasingly prevalent worldwide, affecting both developed and developing countries. This condition results from the deposition…
Abstract Number: 1073 • ACR Convergence 2024
Dashboard Utilization and Order Menu Revision Improve HLA-B*5801 Testing Prior to Allopurinol Initiation in High-Risk Patients in a Veteran-based Primary Care Setting
Catherine Vo, Chialin Nguyen, Scott Hagan, Sheida Aalami and Elizabeth Wahl, VA Puget Sound Healthcare System, Seattle, WA
Background/Purpose: The 2020 ACR Guideline for the Management of Gout conditionally recommends testing for the HLA-B*5801 risk allele prior to starting allopurinol for patients of…

« Previous Page
1
…
4
5
6
7
8
…
49
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].